In 2018, the European Food Safety Authority (EFSA) was asked by the European Commission to deliver a Scientific Opinion on three Terms of Reference (ToRs) related to chronic wasting disease (CWD): (ToR1) to revise the state of knowledge, considering new scientific data, about the differences: a) between the strains found in different species in North America (NA) and in Europe and b) between the strains found so far in moose, reindeer and red deer in Europe, with the main emphasis on transmissibility (transmission paths), pathogenicity and prevalence of the different strains and susceptibility of the different species/genotypes; (ToR2) to revise the new scientific evidence on the zoonotic potential of CWD, to assess the risk of transmission to humans through the consumption of fresh meat, meat products and offal of cervids and to provide recommendations on possible additional control measures to address the risks identified; and (ToR3) to identify risk factors that can facilitate the spread of CWD in the European Union given the current situation of the disease.
To source the relevant data, the extensive literature searches used in the previous recent EFSA Scientific Opinions on CWD (EFSA BIOHAZ Panel, 2017, 2018) were updated. In addition, research groups known to be conducting bioassay transmission studies and molecular/biochemical studies (protein misfolding cyclic amplification (PMCA), real-time quaking-induced conversion (RT-QuIC), PrPres typing, conformational stability, proteinase K (PK) resistance, etc.) to characterise and the transmissibility of CWD field isolates from cases confirmed in Norway/Finland and in NA were asked to provide additional pre-publication data. Regarding risk factors, the strength of the evidence for the causal role of each factor was appraised, based on study design and a score-based ranking from the strongest evidence (intervention studies) to the weakest (theoretical biological plausibility) was applied. Full characterisation of European isolates is being pursued through the collection of data on host species spectrum and genotype, clinical presentation, histopathology, immunopathology, tissue distribution, pathogenesis, the biochemical properties of the PrPSc, and bioassay through experimental transmission to a wide range of rodent models, whereas most NA CWD isolates have not been fully characterised in this way. However, preliminary data support the contention that the CWD strains identified to date in Europe and NA are different and suggest the presence of strain diversity in the European cervid population. The origin(s) of CWD in Europe remains unknown, and while it is clear that the disease identified in the reindeer in Nordfjella is contagious, the nature of the prion disease in the other species (the European moose and red deer) is still to be established.
NA CWD has been transmitted experimentally to cattle and sheep, but with incomplete attack rates. The species barrier appears higher for pigs, although challenged animals can support low-level prion amplification. Experimental transmission to transgenic (tg) mice and other rodent models shows some difference in the host ranges of different isolates but, particularly for the European isolates, many bioassays are still ongoing and data are not yet available. The number of strains, the strain diversity, the prevalence and the potential host range of disease in both NA and Europe CWD may all be underestimated.
In vitro studies suggest that CWD isolates derived from experimentally challenged reindeer, and elk with a specific PRNP polymorphism (132 MM) would present an intermediate potential of conversion of human PrP to disease-associated PrPSc. Some studies have shown that exposure to some NA CWD isolates can result in the conversion of human PrP in vitro and that some NA CWD isolates can transmit disease efficiently to squirrel monkeys. However, in vivo studies performed with humanised mice and macaques are considered to be the most pertinent models of human susceptibility and there is conflicting evidence on the transmissibility of NA CWD isolates in these models.
Epidemiological studies suffer from many methodological limitations and logistic constraints and some of them are still ongoing in NA but, until now, there is no epidemiological evidence of NA CWD causing disease in humans. The risk to humans through consumption of meat, meat products and offal derived from CWD-infected cervids cannot be directly assessed. At individual level, consumers of meat, meat products and offal derived from CWD-infected cervids will be exposed to the CWD agent(s). At the population level, the probability of exposure via consumption of venison depends on the prevalence of CWD agent(s) in each of the species that are consumed (reindeer, moose, red deer), which is not known. Preliminary testing of animals intended for human consumption with removal of any carcases that test positive, or the removal of high-risk tissues from cervids intended for human consumption, or the combination of these measures, would reduce the probability of dietary exposure of humans to the CWD agent(s). The prohibition of harvesting/hunting susceptible species in infected premises/areas could also be considered as a preventive measure.
Current EU legislation requires a 3-year monitoring programme for CWD from 1 January 2018 to 31 December 2020 to be implemented in six Member States (MSs) that have a wild and/or farmed and/or semi-domesticated population of moose and/or reindeer: Estonia, Finland, Latvia, Lithuania, Poland and Sweden. In 2018, the six MS tested a total 5,110 cervids, of which 4,674 (91.5%) were wild animals, mostly roe deer and red deer, and 436 (8.5%) were captive, farmed or semi-domesticated, with more than half of them being semi-domesticated reindeer tested in Finland. Over 59% of all cervids tested were from healthy hunted/slaughtered fit for human consumption animals, whose probability of disease is lower than that of sick animals, road kills or fallen stock. Up to 20 September 2019, 28 cases have been reported in Europe: 19 wild reindeer, 4 moose and one red deer in Norway, one moose in Finland and three moose in Sweden.
Using data from the NA CWD experience, 13 groups of risk factors have been identified based on their biological plausibility to spread CWD. Some of these are supported by epidemiological evidence from NA CWD studies with variable strength of evidence after applying the score-based ranking, while others remain hypothetical:
9) Fallen stock or inappropriate disposal of carcasses and slaughter by-products,
13) Host genetics.
All the identified risk factors may contribute to the spread of the disease when it is associated with the accumulation of infectivity in peripheral tissues, a host phenotype that is compatible with a contagious disease. A subset of risk factors (1, 2, 6, 8, 9, 10, 11, 12 and 13) is relevant to cases of disease that do not involve peripheral accumulation of infectivity and are therefore less contagious or non-contagious and may contribute to the spread of the disease mainly via environmental contamination following death. Some risk factors are man-mediated and are considered preventable. Their management could contribute to the decrease in the theoretical risk of spread of CWD. The potential co-localisation of cervid species and disease phenotypes mean that all the identified groups of risk factors should be taken into account when considering interventions.
It is recommended: (1) to document PRNP gene polymorphisms (nature, distribution and frequency) in European cervid populations; (2) to collate data to fully characterise European CWD isolates and collect data on new cases that may arise in Europe, together with NA positive control material; (3) to collect data on tissue distribution in naturally infected animals and, ideally, through experimental pathogenesis studies in cervid species; (4) and to maximise the effectiveness of the current compulsory surveillance by aiming at testing primarily animals in the risk groups and increasing sample size per primary sampling unit (PSU) (up to 30 at risk animals).
3. Assessment
3.1. Summary of the knowledge about CWD strains and their pathogenesis
Due to the incomplete understanding of the nature and molecular characteristics of prion strains, ‘strain typing’ currently relies on characterising the disease phenotype in the host, using a range of approaches including clinical presentation, histopathology and immunopathology, the biochemical properties of the PrPSc and bioassay through experimental transmission to well-established rodent models. These represent the only approaches available for the identification of prion strains, but they all have their own intrinsic limits, which impact on the final relevance of the results they provide and, on the nomenclature, used to describe the strain(s) identified within any TSE isolate.
It is beyond the scope of this opinion to exhaustively describe such methods, but more detailed reviews of these techniques can be found elsewhere (Bruce, 2003; Boyle et al., 2017) and a summary of some key points is provided in Appendix A, for ease of reference.
3.1.1. North America
Seminal transmission studies of NA CWD isolates in cervid-PrP-expressing transgenic (tg) mice (Browning et al., 2004; LaFauci et al., 2006) indicated the possibility of CWD strain variation.
Since then, there have been further transmission studies of NA CWD isolates to cervid- and noncervid-PrP expressing animals supporting the contention that several prion strains are responsible for the CWD cases observed in NA (Tamguney et al., 2006, 2009a; Johnson et al., 2011; Sigurdson et al., 2011; Crowell et al., 2015; Duque-Velasquez et al., 2015; Triscott et al., 2015; Herbst et al., 2017; Bian et al., 2019). However, due to a lack of consistency between the studies (i.e. no use of common reference isolates/strains) and differences in methodological approaches (i.e. different animal models), comparing and/or merging data from individual studies remains difficult.
Beyond these limitations, two studies originating from the same research group have provided valuable insights into the diversity of CWD strains in NA (Angers et al., 2010; Telling, 2011). The inoculation of a relatively large panel of isolates from various species and geographic locations in NA into transgenic mice overexpressing cervid PrP, indicated the presence of at least two CWD prion strains, referred to as CWD1 and CWD2, that circulate either independently or as a strain mixture. These results were consistent with transmission studies carried out using other models and CWD isolates (Tamguney et al., 2006; Di et al., 2013). Despite consistent differences in the incubation time and neuropathological profiles in cervid mice, the PrPres western blot (WB) banding patterns in the brains of mice infected by either CWD1 or CWD2 were indistinguishable from one another (Angers et al., 2010).
While the existence of at least two CWD strains in North America should be considered as an established fact, it is unlikely that the strain typing work carried out so far has provided a comprehensive or definitive picture of the diversity of CWD strains that are circulating in NA cervid populations.
CWD pathogenesis has been investigated using both naturally exposed and experimentally challenged animals and a full description of these studies can be found in a previous opinion (EFSA BIOHAZ Panel, 2017).
In summary, natural exposure apparently occurs by the oral route, through direct contact between individuals or via a contaminated environment (Moore et al., 2016a). Pathogenesis and abnormal PrP distribution in CWD are very similar to that reported in classical scrapie in small ruminants with susceptible genotypes (EFSA BIOHAZ Panel, 2014).
Following experimental challenge by the oral route, initial entry of the agent occurs through the gut-associated lymphoid tissue (GALT) with rapid involvement of the lymphoreticular system (LRS) and passage to the enteric nervous system (ENS). The CWD agent(s) then spreads to the CNS via autonomic nervous structures (Sigurdson et al., 1999, 2002; Fox et al., 2006). Early prion infectivity/ seeding activity has also been observed in the blood during the preclinical phase of the incubation period (Mathiason et al., 2006; Kramm et al., 2017).
Race et al. (2007) concluded that the involvement of the LRS seems to vary between deer and elk, with less abnormal PrP deposition in the lymphoid tissues of elk compared with deer. It is unclear at this stage whether such variations are the consequence of differences in CWD strains with differing lymphotropism and/or host PrP gene polymorphisms, or both.
A limiting factor for the understanding of the diversity of natural disease is that surveillance has not been consistently applied in NA, with some regions undertaking initial screening of lymphoid tissues only. This means that animals in which PrP accumulation is largely, or completely, limited to the CNS (as is the case for the European moose and red deer) would not be detected or investigated.
The possibility of such cases having occurred undetected is supported by the recent report of the first confirmed case of CWD in a farmed red deer in the province of Quebec in Canada in 2018, in a region where no cases of CWD had been confirmed before. The index case was a 15-month-old male, clinically healthy at slaughter. The initial enzyme-linked immunosorbent assay (ELISA) test was positive in the brain stem but negative in the lymph node, even though a low level of abnormal PrP was subsequently detected by immunohistochemistry (IHC) in a low number of follicles in the lymph node. Following the cull of the herd, over 1700 red deer were tested and an additional 10 cases of CWD were identified in females ranging in age from 18 to 28 months. All cases were positive in the obex by ELISA, IHCand WB, although the extent of abnormal PrP deposition detected by IHC was somewhat variable. A higher degree of variability in abnormal PrP accumulation was found in lymphoid tissues, with no detection by IHC in the tonsils of several cases (Walther et al., 2019). This presentation of the first outbreak of red deer in NA resembles that of a disease that is transmitted animal-to-animal, facilitated by the high density of animals, leading to high contact rates and local environmental contamination that favour horizontal transmission of disease, as opposed to the situation in wild populations.
In animals incubating CWD, abnormal PrP and/or infectivity has been demonstrated in placenta, saliva, faeces and urine which are all likely to contribute to inter-individual transmission but also to the general contamination of the environment (Mathiason et al., 2006; Tamguney et al., 2009a; Haley and Hoover, 2015; Plummer et al., 2017).
Abnormal PrP and/or prion seeding activity and/or prion infectivity has been detected in a large number of tissues (see Table 1 in EFSA BIOHAZ Panel, 2017), in particular in those commonly consumed as venison (heart, skeletal muscles, tongue, liver, kidneys) or used as dietary supplements (antler velvet) (Sigurdson et al., 2001; Angers et al., 2006, 2009; Mitchell et al., 2012). Unfortunately, in most instances, it is difficult, or not possible, to derive a quantitative estimate from the published data (Section 3.4.2) of the amount of prion/seeding activity in these tissues.
3.1.2. Europe
Due to their recent identification, the characterisation of the EU CWD cases remains incomplete. The amount of data related to the pathogenesis of the prion disease(s) identified in these animals is extremely limited as they are all field cases and most of the samples are autolysed.
In Norwegian reindeer, the presence of PrPSc in certain lymphoid organs (including in cases in which no abnormal PrP is detected in the CNS) suggests a pathogenesis similar to that of most NA cervids. However, because of the potential impact of CWD strain and/or PrP genetics on the pathogenesis of prion disease, the final distribution and level of prion infectivity in tissues of incubating and affected animals could significantly differ between EU and NA cervids. The PrPres WB patterns obtained from Norwegian reindeer were similar to those observed in an American elk CWD sample and Canadian CWD isolates including reindeer orally inoculated with NA CWD material. The immunohistochemical (IHC) distribution of PrPSc in the obex, the cerebellum and the lymph nodes was also similar to that of Canadian reindeer orally challenged with CWD (Mitchell et al., 2012; Benestad et al., 2016; Moore et al., 2016a).
Investigations carried out on three of the four positive moose cases (Alces alces) identified in Norway, for which lymphoid tissues were available, revealed the presence of detectable PrPSc in the brain but not in lymphoid tissues. Immunohistochemistry revealed that the Norwegian moose shared a common neuropathological phenotype (mainly intraneuronal staining) that clearly differed from that observed in both Norwegian reindeer and in CWD-infected NA cervids. Moreover, WB revealed a PrPres banding pattern that clearly differed from CWD cases reported so far in NA cervids and in Norwegian reindeer (Pirisinu et al., 2018). The absence of detectable abnormal PrP in the lymphoid tissues of the Norwegian, Swedish (Gavier-Widen, 2019) and Finnish moose (Korpenfelt, 2019) and the red deer (Vikøren et al., 2019), in which prion disease has been confirmed, clearly supports this contention and also suggests that in the EU, distribution patterns and level of accumulation of prions in tissues might significantly vary according to the prion strains and/or cervid species. Any extrapolation from the studies reviewed and summarised in EFSA’s Scientific Opinion (EFSA BIOHAZ Panel, 2017) to cases arising in the European context should therefore be undertaken with caution.
There are no published data related to the molecular characterisation of the Norwegian red deer isolate, but personal communication from Norway (Benestad, 2019a) indicates that this isolate has a WB pattern that is different from both the Norwegian moose and reindeer and from CWD from North America. It does have some similarities with bovine spongiform encephalopathy (BSE), but the presence of BSE has been formally ruled out as a possibility by the EURL Strain Typing Expert Group (STEG) by sPMCA methods aiming at identifying the BSE strain in an isolate (Gough et al., 2014). As for the Norwegian CWD moose, no PrPSc was detectable in the lymph nodes and tonsils of this red deer (Vikøren et al., 2019).
Another feature of the European moose and red deer CWD cases is their advanced age, all between 13 and 16 years for the moose and 16 years for the red deer, as opposed to the CWDaffected Norwegian reindeer that were aged between 1.5 and 8 years.
Transmission experiments to strain type the Norwegian CWD isolates are still ongoing, and therefore, definitive results are not yet available. Characterisation of the isolates from the four cases recently identified in elderly moose in Sweden and Finland is ongoing (see Section 3.5). The origin(s) of CWD in Europe remain unknown and while it is clear that the disease identified in the reindeer in Nordfjella is contagious, the nature of the prion disease in the other species (the European moose and red deer) remains to be established.
3.1.3. Concluding remarks
• A lack of consistency in methodologies makes comparison of data from different individual studies difficult. Although the strain typing work carried out so far has not provided comprehensive data on the CWD strains circulating in NA cervid populations, at least two CWD prion strains (CWD1 and CWD2) are responsible for disease in North America.
• The pathogenesis of NA CWD typically starts with the accumulation of abnormal PrP in the lymphoid tissues, with subsequent involvement of the CNS. The extent of involvement of the LRS seems to vary between deer and elk. However, the first NA red deer case was positive in the brainstem and negative in lymphoid tissue with the primary ELISA screening test, although low levels of PrP accumulation were subsequently detected in lymphoid tissue.
• NA surveillance has relied, in some regions, on the primary screening of lymphoid tissues only. Animals in which PrP accumulation is largely, or completely, limited to the CNS may not be detected by this method.
• Disease pathogenesis in Norwegian reindeer is similar to most NA CWD cases. However, the Norwegian moose share a common neuropathological phenotype that differs from that
observed in both Norwegian reindeer and in NA CWD cases. The Norwegian red deer isolate has a Western Blot pattern that is different from both the Norwegian moose and reindeer and from NA CWD.
• The laboratory characterisation of European cervid TSE cases remains incomplete.
snip...
3.2.1.2. Non-cervid domestic species
The remarkably high rate of natural CWD transmission in the ongoing NA epidemics raises the question of the risk to livestock grazing on CWD-contaminated shared rangeland and subsequently developing a novel CWD-related prion disease. This issue has been investigated by transmitting CWD via experimental challenge to cattle, sheep and pigs and to tg mouse lines expressing the relevant species PrP.
For cattle challenged with CWD, PrPSc was detected in approximately 40% of intracerebrally inoculated animals (Hamir et al., 2005, 2006a, 2007). Tg mice expressing bovine PrP have also been challenged with CWD and while published studies have negative outcomes (Tamguney et al., 2009b), unpublished data provided for the purposes of this Opinion indicate that some transmission of individual isolates to bovinised mice is possible (Table 1).
In small ruminant recipients, a low rate of transmission was reported between 35 and 72 months post-infection (mpi) in ARQ/ARQ and ARQ/VRQ sheep intracerebrally challenged with mule deer CWD (Hamir et al., 2006b), while two out of two ARQ/ARQ sheep intracerebrally inoculated with elk CWD developed clinical disease after 28 mpi (Madsen-Bouterse et al., 2016). However, tg mice expressing ARQ sheep PrP were resistant (Tamguney et al., 2006) and tg mice expressing the VRQ PrP allele were poorly susceptible to clinical disease (Beringue et al., 2012; Madsen-Bouterse et al., 2016). In contrast, tg mice expressing VRQ sheep PrP challenged with CWD have resulted in highly efficient, life-long asymptomatic replication of these prions in the spleen tissue (Beringue et al., 2012).
A recent study investigated the potential for swine to serve as hosts of the CWD agent(s) by intracerebral or oral challenge of crossbred piglets (Moore et al., 2016b, 2017). Pigs sacrificed at 6 mpi, approximately the age at which pigs reach market weight, were clinically healthy and negative by diagnostic tests, although low-level CWD agent replication could be detected in the CNS by bioassay in tg cervinised mice. Among pigs that were incubated for up to 73 mpi, some gave diagnostic evidence of CWD replication in the brain between 42 and 72 mpi. Importantly, this was observed also in one orally challenged pig at 64 mpi and the presence of low-level CWD replication was confirmed by mouse bioassay. The authors of this study argued that pigs can support low-level amplification of CWD prions, although the species barrier to CWD infection is relatively high and that the detection of infectivity in orally inoculated pigs with a mouse bioassay raises the possibility that naturally exposed pigs could act as a reservoir of CWD infectivity.
3.2.1.3. Other species
Studies have demonstrated that the CWD agent(s) can be transmitted by the IC route in several species of rodents, such as voles (Subfamily Arvicolinae), deer mice (Peromyscus maniculatus), mice and hamsters (Subfamily Cricetinae). The susceptibility was, however, variable, being high in voles and deer mice but lower in mice and hamsters (Raymond et al., 2007; Heisey et al., 2010; Kurt et al., 2011; Di et al., 2013; Lee et al., 2013). Mink (subfamily Mustelinae) (Harrington et al., 2008), ferrets (Mustela putorius) (Bartz et al., 1998; Sigurdson et al., 2008) and cats (Mathiason et al., 2013) were susceptible to IC challenge with NA CWD sources, while CWD transmitted poorly to raccoons (Procyon lotor) by the IC route (Moore et al., 2019).
3.2.2. European isolates
The host range of CWD in Europe has been much less investigated so far, due to its recent identification. Among the cervid species involved in the CWD epidemics in North America, only some species (such as moose and reindeer) inhabit Europe; mule deer, white-tailed deer and elk/wapiti are American cervid species, although a few populations of white-tailed deer have been introduced into Europe. Others cervids that mainly inhabit Europe are red deer and roe deer. After the first detection in a reindeer in Norway in 2016 (Benestad et al., 2016), CWD has been detected in wild reindeer, moose and one red deer in Norway (Mysterud and Edmunds, 2019), in a moose in Finland in March 2018 and in three moose in Sweden in March, May and September 2019. CWD has not been detected so far in wild roe deer, fallow deer or white-tailed deer nor in any farmed cervid species. However, for fallow deer and white-tailed deer, the number of animals tested by the surveillance systems is still very low.
The potential host range of European CWD strains is under investigation by bioassay experiments in a range of model species; most of these studies are ongoing and there are no published data available so far. Data from the experiments that are known to be ongoing in different laboratories have been gathered for the purposes of this Opinion. Overall, reindeer CWD, moose CWD and red deer CWD brain isolates (and LRS isolates from some selected cases) are being tested for transmissibility in mice, hamsters, bank voles and in a range of tg mouse lines expressing PrP sequences from: cervids (Q226 or E226 deer PrP variants), small ruminants (ARQ, VRQ, AHQ and ARR PrP polymorphic variants), cattle, pig, vulture and human (M129 and V129 PrP polymorphic variants) (see Section 3.3.1). Importantly, in most of these animal models, the transmissibility of European CWD isolates will be directly comparable with the outcome of similar (published or ongoing) experiments with CWD isolates from North America.
While most of these studies are still ongoing, some experiments with CWD isolates from Europe have already produced evidence of transmission in some recipient species (Table 1). These include bank voles, conventional laboratory mice and tg mice expressing cervid PrP, sheep PrP and mouse PrP. The same rodent models are also susceptible to NA CWD isolates and will therefore allow comparative strain typing of NA and European CWD strains in due course. There is no strong evidence so far for rodent models being widely susceptible to NA isolates but not to European isolates or vice versa.
Table 1 summarises more than 500 ongoing, published or unpublished primary transmission experiments of NA or European CWD isolates from different cervids into various rodent models, which have been gathered following the requests described in Section 2.2. The CWD isolates are grouped according to geographical origin and cervid species, with each column summarising the results obtained with one or more CWD isolates from a given species and country. Rodent models are grouped according to the PrP species expressed. Some species have polymorphic PrP sequences, so more than one PrP sequence per species has been modelled. In these cases, each row summarises the data obtained with more than one PrP variant of a given species. Therefore, conventional mice include wt mice expressing PRNPa or PRNPb mouse PrP variants; bank voles include two genetic lines with different amino acids at codon 109 (Bv109M and Bv109I); tg-cervidPrP mice include mouse lines expressing several cervid PrP variants (the deer wt Q226, the elk wt E226, the WTD variant S96, the elk variant M132); tg-sheepPrP mice include mouse lines expressing the ARQ, VRQ, AHQ or ARR small ruminant PrP variants; finally, tg-humanPrP mice include mouse lines expressing M or V at the human PrP polymorphic codon 129. Therefore, each box in the Table 1 summarises the outcome of bioassay experiments with one or more CWD isolates (from the same species and origin) in one or more recipient rodent models (expressing PrP from a single given species).
Table 1: Summary of the state of research on experimental transmission models of CWD isolates in North America and Europe
snip...
Most of the studies conducted by molecular/biochemical methods are still ongoing. The preliminary data obtained by molecular/biochemical methods were difficult to summarise and will not be reported in the present Opinion. This was mainly due to lack of detail in the results obtained by direct PrPSc analyses (PrPres typing, conformational stability, proteinase K resistance, which are intended to investigate CWD strains) and to the different methodological approaches employed in amplification assays (PMCA and RT-QuIC). The information gathered by this activity shows that experiments aimed at modelling the species barrier for NA or European CWD isolates into different animal species, including humans, are underway in different laboratories and will be of help for understanding the potential host range of CWD strains.
3.2.3 Impact of the PRNP gene on transmissibility
Polymorphisms in the PRNP gene are known to influence susceptibility/resistance to prion disease in both small ruminants and humans (for recent review, see EFSA BIOHAZ Panel 2014, EFSA BIOHAZ Panel, 2017; Diack et al., 2014). Effects of host PRNP polymorphisms on CWD susceptibility/resistance have also been described in a number of cervid species (reviewed in EFSA BIOHAZ Panel, 2017, 2018). However, deer and elk wild-type PrP primary structures are equivalent, except at residue 226, which is glutamate in elk and glutamine in deer. The effect of this difference on CWD pathogenesis has been recently investigated using a gene-targeting approach in which the mouse PrP coding sequence was replaced with elk or deer PrP. The results obtained following experimental challenge with deer and elk CWD inocula from NA showed that the resulting GtE226 and GtQ226 mice had distinct kinetics of disease onset, with incubation times shorter in GtE226 than in GtQ226 mice, indicating that amino acid differences at PrP residue 226 dictate the selection and propagation of divergent strains in deer and elk with CWD. As prion strain properties largely dictate host range potential, these findings suggest that prion strains from elk and deer might pose distinct risks to sympatric species or humans exposed to CWD (Bian et al., 2019).
The most common cervid species in Europe (moose, red deer, reindeer and roe deer) share the same PrP primary structure, i.e. Q226. However, red deer PrP is polymorphic at residue 226 and can therefore code for either Q226 or E226. Interestingly, CWD cases detected so far in four Norwegian moose, the first Swedish moose and one Norwegian reindeer are all homozygous for Q226 (Benestad, 2019b,c,d), but the CWD case in red deer is instead homozygous for E226 (Vikøren et al., 2019). The impact of these differences in PrP genotype on the transmissibility and strain properties of European CWD isolates is currently under investigation using GtE226 and GtQ226 mice (Bian et al., 2019). PRNP genotypes of the other reindeer from Norway and of the other moose cases in Sweden and Finland are not in the public domain.
Data on the transmissibility of CWD in species with different PrP sequences obtained by in vivo or in vitro modelling allow the investigation of the structural basis of the transmission barriers for CWD. This in turn could provide hints for predicting, to some extent, the susceptibility of non-cervid species to CWD. Taken together, studies with CWD isolates from NA suggest that the 165–175 sequence similarity between cervid and host PrP is one important factor governing the susceptibility of different species to CWD (reviewed by Kurt et al., 2016). In particular, polymorphisms at N/S170 in the recipient species might be important for susceptibility, with species that have N170 being more susceptible than those with S170 (Kurt et al., 2016). However, this must not be seen as an absolute rule, as species having S170 in their PrP, such as squirrel monkeys, have also been reported to be susceptible to CWD. It is however pertinent to note that all livestock species and humans have PrP sequences with S170, so they should not be considered among the species with supposedly high susceptibility to NA CWD isolates. Ongoing experiments in rodent models seem to indicate a similar trend for European CWD isolates, as rodent models, apparently more susceptible to European CWD isolates such as bank voles and tg mice expressing deer PrP, are N170.
Little information is currently known about the genetics of either wild or farmed cervid populations in Europe. A recent published study of several deer species (mostly in Great Britain) reported that red deer showed the most PRNP gene variation, with polymorphisms at codons 98, 168, 226 and 247 and marked variability in genotype frequencies in different regions. Other deer species showed less variation, with roe and fallow deer having identical PRNP gene sequences in all the animals sampled. Based on comparison with PRNP sequences of NA cervids affected by CWD and limited experimental challenge data, the authors conclude that a high proportion of wild deer in Great Britain may be susceptible to CWD (Robinson et al., 2019). A similar conclusion was reached by a previous study of 715 genotyped cervids (red deer, roe deer and chamois) from the UK and Italy (Peletto et al., 2009).
3.2.4. Concluding remarks
• The transmission of prions between species is limited by the ‘transmission barrier’ and the amino acid sequence of the host PrP plays a very key role in the overall susceptibility to TSE. Even for prions deriving from the same species, the host range may vary according to the prion strain, implying that different CWD strains might have different host ranges and different potential for transmitting to livestock species and to humans.
• Whether the natural host range of CWD in NA extends beyond the family Cervidae is currently unclear and no natural infections have been reported so far in other wildlife species (e.g. predators and scavengers) with overlapping geographical ranges.
• NA CWD has been transmitted experimentally to cattle and sheep, but with incomplete attack rates. The species barrier appears higher for pigs, although challenged animals can support low-level prion amplification.
• Experimental transmission to tg mice and other rodent models shows some difference in the host ranges of different isolates but, particularly for the European isolates, many bioassays are still ongoing and data are not yet available.
• The number of strains, the strain diversity, the prevalence and the potential host range of disease in both NA and Europe CWD may be underestimated.
3.3. Transmissibility to humans: the zoonotic potential
The zoonotic potential of CWD has been addressed by several research groups through in vitro and in vivo approaches. However, it must be underlined that, at the time of writing this Opinion, the corresponding publications report results only based on CWD isolates derived from naturally or experimentally infected cervids from NA and none with isolates from Europe.
3.3.1. In vitro conversion of human PrP
Several approaches developed for converting PrP in vitro have been proposed to model the species barrier (EFSA BIOHAZ Panel, 2015). These techniques are based on the ability of infected samples (here derived from animals) to convert normal (here human) PrP (PrPc ) in vitro under different experimental conditions. For these studies, the PrP substrate submitted to conversion can be either recombinant PrP or a brain homogenate. The latter source not only has the advantage of being able to present the natural diversity of PrP isoforms, but other components (e.g. nucleic acids, proteins, lipids) are also present with their potential influence on the reactions of conversion (e.g. co-factors, inhibitors).
The conversion of human recombinant PrPc (recPrPc ) triggered by NA CWD isolates is very limited, if any, in comparison with the conversion induced by other prion sources reputed to be efficiently infectious for humans. Therefore, in the presence of sodium dodecyl sulfate (SDS), human recPrPc was efficiently seeded by sporadic Creutzfeldt–Jakob disease (sCJD) or BSE purified infectious samples, but not by scrapie or white-tailed deer CWD samples (Luers et al., 2013). Conversely, the RT-QuiC technique of PrP amplification was efficient with eight different isolates derived from CWD-infected white-tailed deer, compared with BSE, which fails to convert human recPrP with this technique (Davenport et al., 2015). In the presence of guanidine, elk and mule deer PrPSc are able to induce a limited conversion of methionine homozygous at codon 129 (MM) human recPrPc (these CWD seed sources converted homologous cervid recPrPc with a 15-fold higher conversion rate) but did not convert valine homozygous at codon 129 (VV) human recPrPc (Raymond et al., 2000). Similar levels of conversion of human recPrPc were obtained with scrapie-infected ovine PrPSc, whereas BSE-infected bovine PrPSc was slightly more efficient at converting human recPrPc (conversion rate ninefold less efficient than with homologous PrPc ).
The conversion of human PrPc by CWD seeds was more efficient when normal brain homogenates were used as the source of normal PrP. Amplification studies based on the PMCA technique have demonstrated that the efficiency of in vitro conversion of human PrP is highly influenced by the PrP polymorphisms of the human recipient, PrP polymorphisms of the cervid donor and the origin of the isolates (Barria et al., 2018). In cervids, the polymorphism at codon 132 (methionine or leucine) plays an important role in CWD susceptibility (Hamir et al., 2006c), as does the polymorphism at codon 129 (methionine or valine) for humans with regard to susceptibility to CJD. With elk CWD samples, ‘only the homologues methionine homozygous seed-substrate reactions could readily convert the human PrP’ (132 MM elk sample on 129 MM human PrP) whereas other combinations were less efficient (Barria et al., 2018). However, the rate of conversion of human PrPc by elk CWD samples remains lower than the conversion observed with BSE samples, but higher than the conversion induced by L-BSE, H-BSE or scrapie (Barria et al., 2014). Also, efficient PMCA conversion and amplification of human PrPc of the three human genotypes (MM, MV and VV) were observed with infectious materials derived from two reindeer experimentally infected with CWD (Barria et al., 2018). Conversely, PMCA amplification was very limited with white-tailed deer (Barria et al., 2018) and mule deer CWD samples (Barria et al., 2011). In the latter, the species barrier was broken through serial amplifications of mule deer CWD on a homologous substrate, suggesting that, after serial intraspecific passages, the zoonotic potential of CWD (if any) might increase. Other parameters (like the low pH of the lumen of the stomach) might influence susceptibility to CWD (Li et al., 2007): the rate of conversion of human PrPc by CWD-infected elk brain in the presence of guanidine is highly enhanced (reaching similar levels of conversion to those obtained for cervid PrP) in acidic conditions but not in neutral conditions. Table 2 describes the main in vitro studies exploring the zoonotic potential of CWD by assessing the conversion of human PrP in the presence of CWD seeding material.
Table 2: Summary of the in vitro studies aimed at exploring the human species barrier to CWD
snip...
Taken together, these in vitro studies suggest that, within the limits of the ruminant isolates that were used in them,
• BSE (established zoonotic potential) presents the highest ability to convert human PrP;
• CWD isolates derived from (132 MM) elk and experimentally challenged reindeer would present an intermediate potential for conversion of human PrP;
• other sources would be less efficient at converting human PrP. This includes CWD isolates derived from deer, atypical H-BSE and L-BSE strains or scrapie isolates, even if the zoonotic potential of atypical BSE and scrapie is supported by experimental evidence of transmission in tg humanised mice (Beringue et al., 2008a; Cassard et al., 2014) and non-human primates (Gajdusek, 1972; Gibbs and Gajdusek, 1973; Comoy et al., 2008, 2015; Ono et al., 2011).
3.3.2. In vivo studies of zoonotic potential of CWD isolates
Transgenic mice expressing human PrP and non-human primates are the two classes of in vivo experimental models used to evaluate the zoonotic risk of animal prions for humans.
3.3.2.1. Transgenic humanised mouse models
Several tg humanised mice lineages based on key polymorphisms at codon 129 of the human PRNP gene (six lineages of MM, one lineage of MV and two lineages of VV) expressing onefold to 16-fold the physiological levels of PrPc have been exposed to NA CWD isolates derived from elk, mule deer or white-tailed deer in the context of six independent experiments. No clinical, histopathological or biochemical evidence of neurological prion disease has been observed in any of these mice, even after extended incubation periods. According to these results, there is a high transmission barrier to humans for CWD. Nevertheless, this conclusion should be modulated by the fact that no blind secondary miceto-mice transmission was performed in any of these studies. Indeed, this approach in tg humanised mice resulted in the conclusion that some zoonotic potential for scrapie could not be ruled out (Cassard et al., 2014).
Table 3 describes the main in vivo studies exploring the transmissibility of CWD to humanised transgenic models and non-human primate species as proxies for the zoonotic potential of CWD.
Table 3: Summary of the in vivo studies exploring the transmissibility of CWD to humanised transgenic models and non-human primate species
snip...
Nevertheless, Race et al. (2019) recently published a study performed with two lineages of humanised mice that provided intriguing results. They exposed tgRM and tg66 mice, which overexpress MM human PrP at levels two- to fourfold and 8- to 16-fold higher than the physiological levels, respectively, to different CWD sources. These two models harbour the highest levels of PrPc expression among all those that have been tested in these studies. Among these mice, 7% (3/45) tgRM and 30% (15/52) tg66 mice fitted the ‘criteria as prion disease suspects’ that the authors considered to be relevant and that correspond to ‘signs of wasting, weakness, neurologic disease and behavioural changes’ (Race et al., 2019). Extensive analyses of the brains of these animals did not provide any lesional, biochemical or immunohistochemical element that could confirm the diagnosis of prion disease and the authors expressed some reservations about the relevance of those observations because of the advanced age of these animals (> 500 days of incubation). In parallel, the authors analysed the brains of all the inoculated animals using RT-QuIC. Four tg66 mice exposed to CWD samples were identified with repeated positive reactions (nine other exposed animals showed initial, positive reactions that were not reproducible). The authors wonder whether ‘the seeding activity detected in these mice may represent a low level of CWD agent, suggesting a possible transfer of CWD infection’, or ‘these results might be due to false-positive reactions or residual CWD inoculum’. Unfortunately, the authors did not indicate whether the animals that exhibited a positive RT-QuIC reaction were those that were clinically suspect.
It must be noted that the authors did not test the spleens of these animals. Indeed, during Prion 2015 (Fort Collins) and Prion 2019 (Edmonton) conferences, Kong et al. reported in oral presentations the partial transmission at subclinical levels of CWD to humanised mice (different transgenic constructions), with splenic involvement (Comoy et al., 2019a). This situation is reminiscent of observations made in humanised mice exposed to variant Creutzfeldt-Jakob disease (vCJD) prion strain (Beringue et al., 2008b). In a similar way, the study of Race et al. (2018) missed the analysis of the spinal cords of these CWD-exposed humanised mice. Indeed, unexpected disease phenotypes selectively affecting spinal cord without brain involvement have been observed in mice and macaques under non-optimal conditions of experimental transmission (Comoy et al., 2017).
3.3.2.2. Chimeric mouse models
Humanised mice that were highly susceptible to CWD were obtained by modifying four amino acids (positions 166, 168, 170 and 174) in red in Table 4 at the level of the a2–b2 loop of the human PrP to perfectly match that of the elk PrP (Kurt et al., 2015). These observations suggest that this part of the prion protein constitutes a substantial structural barrier for CWD transmission to humans. The influence of this protein loop on species barrier might be different for BSE (transmissible to humans) and scrapie (zoonotic potential under question), as cattle and ovine PrP share the same amino acid sequence at the level of the a2–b2 loop that only differ for amino acids 166 and 168 from the human PrP sequence.
Table 4: Comparison of the wild-type PrP sequences of different species (only differences from the sequence of elk PrP are shown) (Schatzl et al., 1995; Li et al., 2007; Kurt et al., 2015). The reference numbers of equivalent amino acids positions (AA) differ among species due to a difference of octapeptides numbers and/or insertion/deletion of AA at the N-terminal part of the PrP. The letters refer to the standard designation for amino acids and the box denotes the section of the PrP corresponding to the a2–b2 loop
snip...
The experiments performed in non-human primate (NHP) models modulate the influence of this a2-b2 loop on the species barrier towards CWD. Squirrel monkeys (subfamily Saimirinae) and CM (Macaca fascicularis) exhibit different susceptibilities to CWD (Race et al., 2009, 2014), whereas they harbour the same amino acids in the a2–b2 loop (i.e. they differ from human at positions 166 and 168 and from cervids at positions 170 and 174).
3.3.2.3. Non-human primate models
In New World NHP squirrel monkeys, CWD from both MD and elk-derived isolates is transmissible through the IC route with incubation periods similar to those obtained with BSE (Marsh et al., 2005; Williams et al., 2007; Race et al., 2009; Piccardo et al., 2012) suggesting a similar susceptibility of squirrel monkeys to these two animal prions. CWD isolates derived from WTD also transmitted disease, but with longer incubation periods despite a higher infectious titre in the inocula. All these cervid isolates also transmitted CWD to squirrel monkeys after exposure through the oral route (Table 5). After secondary transmission, the incubation periods for CWD decreased (Race et al., 2014): all the features of a classical prion disease, namely specific lesions and accumulation of abnormal PrP, reproducible lesional profile and adaptation of the prion strain to the new host, are found in squirrel monkeys after exposure to CWD.
The situation in CM is very different. After intracerebral (six animals) and oral exposure (eight animals) to the same inoculum as those that have transmitted CWD to squirrel monkeys, no clinical, lesional or biochemical evidence of prion disease was identified in macaque recipients (Race et al., 2009, 2014, 2018) and extensive RT-QuIC analyses of their brain did not provide any evidence of seeding. However, it must be underlined that the incubation periods of macaques after primary exposure to animal prions strains through the intracerebral route are classically extended, with BSE developing up to 93 mpi (~ 8 years) and scrapie proving transmissible 118 mpi (~ 10 years) (Comoy et al., 2015). In this study performed at the Rocky Mountain Laboratories (RML) (USA), it can therefore be concluded that four of the six IC-inoculated macaques have been kept under surveillance for too short a period (less than 95 months) to draw any definitive conclusion (Table 6).
Another study (Canadian), described in the background of this mandate and based on exposure of CM to CWD, is still in progress and not yet published. However, intriguing/interim observations have been the subject of several oral presentations. Eighteen 4-year-old female macaques were exposed through intracerebral, oral, intravenous routes and skin scarification to different isolates derived from CWD-infected animals (MD, WTD and elk sources, experimentally or naturally exposed, from USA and Canadian origins). Among these animals, 10 animals were subjected to intense/extensive diagnostic testing. Animals were sacrificed, or died from unrelated causes, less than 90 months after exposure (two animals IC exposed to elk CWD, four animals IC exposed to CWD-infected WTD, one animal orally exposed to brain samples derived from CWD-infected WTD and three animals exposed to muscles derived from CWD-infected WTD and MD). Among these, four (54–81 months of incubation) exhibited behavioural/neurological changes and/or alterations of the general status including anxiety, apathy, ataxia, tremor and wasting. Three of them were diagnosed as diabetic via elevated blood glucose and glycated haemoglobin (HbA1c) levels. It is notable that in the previously mentioned RML study (Race et al., 2018), nine of the 14 macaques were euthanised because they exhibited similar signs associated with neurological manifestations (aggression, seizure or tremor) or metabolic problems (anorexia, wasting, four diabetes cases). Spontaneous diabetes is described in the CM, but it
Table 5: Incubation periods of infected squirrel monkeys after exposure to different prion isolates through the intracerebral route
The situation in CM is very different. After intracerebral (six animals) and oral exposure (eight animals) to the same inoculum as those that have transmitted CWD to squirrel monkeys, no clinical, lesional or biochemical evidence of prion disease was identified in macaque recipients (Race et al., 2009, 2014, 2018) and extensive RT-QuIC analyses of their brain did not provide any evidence of seeding. However, it must be underlined that the incubation periods of macaques after primary exposure to animal prions strains through the intracerebral route are classically extended, with BSE developing up to 93 mpi (~ 8 years) and scrapie proving transmissible 118 mpi (~ 10 years) (Comoy et al., 2015). In this study performed at the Rocky Mountain Laboratories (RML) (USA), it can therefore be concluded that four of the six IC-inoculated macaques have been kept under surveillance for too short a period (less than 95 months) to draw any definitive conclusion (Table 6).
Another study (Canadian), described in the background of this mandate and based on exposure of CM to CWD, is still in progress and not yet published. However, intriguing/interim observations have been the subject of several oral presentations. Eighteen 4-year-old female macaques were exposed through intracerebral, oral, intravenous routes and skin scarification to different isolates derived from CWD-infected animals (MD, WTD and elk sources, experimentally or naturally exposed, from USA and Canadian origins). Among these animals, 10 animals were subjected to intense/extensive diagnostic testing. Animals were sacrificed, or died from unrelated causes, less than 90 months after exposure (two animals IC exposed to elk CWD, four animals IC exposed to CWD-infected WTD, one animal orally exposed to brain samples derived from CWD-infected WTD and three animals exposed to muscles derived from CWD-infected WTD and MD). Among these, four (54–81 months of incubation) exhibited behavioural/neurological changes and/or alterations of the general status including anxiety, apathy, ataxia, tremor and wasting. Three of them were diagnosed as diabetic via elevated blood glucose and glycated haemoglobin (HbA1c) levels. It is notable that in the previously mentioned RML study (Race et al., 2018), nine of the 14 macaques were euthanised because they exhibited similar signs associated with neurological manifestations (aggression, seizure or tremor) or metabolic problems (anorexia, wasting, four diabetes cases). Spontaneous diabetes is described in the CM, but it classically occurs in 1–2% of captive monkeys (Clarkson et al., 1985), often in obese animals that represent less than 20% of the general population (Bauer et al., 2010). A correlation between the onset of obesity and diabetes and the infection with prions (BSE in their case) has been described by other authors (Strom et al., 2014).
The animals included in the Canadian study were tested for the presence of specific hallmarks of prion disease. Throughout oral presentations in congresses and personal communications with WG members, the authors mentioned that they observed an increased PrP staining evidenced by IHC in the substantia gelatinosa of suspected animals (i.e. the upper part of the posterior horns of their spinal cord) and brain areas (Comoy et al., 2019b). They consider that this labelling is reminiscent of what has been observed and described in primates orally challenged with BSE and that did not develop classical BSE but lesions and atypical PrP accumulation confined to the lumbar cord (Holznagel et al., 2013). However, this labelling is considered by several authors to be physiological as it was observed in the spinal cords of control animals in the RML study (Race et al., 2018) and has been observed in the spinal cord of normal animals of other species (Simmons et al., 2011).
Moreover, the authors of the Canadian study reported that abnormal PrPres in WB and positive RT-QuiC reactions were obtained with lumbar cord samples from some suspected macaques.
These two studies provide apparently contradictory results that may be explained by several factors. Indeed, the RML study exposed older individuals (mean 7.2 years, range 5.2–11.4 years except two animals that were 3–4 years old), in contrast to the Canadian study where animals were 4 years old at exposure, as it is customary. Moreover, the sources of inocula were different, and the animals were challenged with larger amounts of inocula in the Canadian study (10 mg vs 5 mg for IC route, 10 g vs 1 g for oral route, oral dosing with 5 kg of muscle per animal in the Canadian study). Definitive conclusions and publication of these studies are now required in order to have more detailed information and more accurate comparisons, including bioassay results in tg mice and bank voles.
It can be concluded from these two studies that after incubation periods of between 5 and 13 years, no classical prion disease with neurological manifestations, spongiform changes and accumulation of abnormal PrP is seen in CM following challenge with CWD. However, it must be remembered that under non-optimal conditions of exposure, two independent studies have reported that BSE/vCJD infection in macaques and mice might lead to the expression of an atypical disease that does not fit the current criteria of prion diseases (Holznagel et al., 2013; Comoy et al., 2017). The observations provided by both the RML and Canadian studies raise the possibility of a similar situation after exposure of primates to CWD.
Table 6: Duration of surveillance periods of cynomolgus macaques exposed to different prion isolates
3.3.3. Concluding remarks
• CWD isolates from NA have shown variable ability to convert human PrP in in vitro studies. In vivo studies have also produced contradictory results, precluding any definitive conclusion about the ability of CWD to cross the human species barrier.
• Extrapolation from the NA situation with regard to zoonotic potential might lead to either an underestimation or an overestimation of the zoonotic potential of the already identified European isolates, which have been shown to be distinct from NA CWD and from each other, based on the biochemical and biological characteristics that have been defined to date.
3.4. The risk to humans from CWD
As described in the EFSA Scientific Opinion on the review of a scientific publication on the zoonotic potential of ovine scrapie prions (EFSA BIOHAZ Panel, 2015), the link between human and animal TSE cases can be addressed ‘directly by conducting molecular/biological comparison to determine the biological and biochemical similarities of TSE isolates from two different species. It can also be addressed through epidemiological studies that could set hypotheses for putative risk factors via descriptive observational studies or via analytical studies aimed at detecting significant associations between exposure (risk factors) and outcome (health event of interest)’.
Previous sections summarise the biological and biochemical characteristics of the different CWD isolates in Europe and NA. There is a lack of knowledge about the ability of the CWD agent(s) to cross the species barrier and to infect humans. No data are available either on other factors that could determine the uptake of the infectious agent by a new host (humans), such as the amount of agent present, the age of the host at exposure and the possible potentiating effects of intercurrent disease or injury of the host. These and many other factors have been speculated to affect the success of infection following exposure, but the precise roles and interdependence (if any) of these factors are not clear. It is therefore not possible to perform a risk assessment of CWD in humans.
3.4.1. Epidemiological studies
The caveats associated with using epidemiological studies to investigate the association between human and animals TSE have all been previously highlighted (EFSA BIOHAZ Panel, 2015). These include the reliability of disease occurrence estimates from surveillance data and the inability to control for the effects of potential confounding factors, such as CWD diversity, host genetics, lag time (potential incubation period of human TSE), ecological fallacy and exposure misclassification.
A systematic review of the current evidence on the transmissibility of CWD prions to humans has been published recently (Waddell et al., 2018), using the criteria set-up through the Grading of Recommendations Assessment, Development and Evaluation (GRADE) (Schunemann et al., 2013). € Three types of studies were assessed: epidemiological studies, in vitro and in vivo experiments. The GRADE of the quality of evidence for the five epidemiological studies assessed suggested that future evidence may be inconsistent with the conclusions of the currently available studies. For the two studies on macaques (see Section 3.3.2), GRADE indicated that there is limited confidence that the results and estimates presented will not change with future research (mainly due to the limited number of studies and observations available). GRADE of the seven studies on humanised transgenic mice, which provided no evidence to support the possibility of transmission of CWD prions to humans, indicated that there is some confidence the overall conclusions of this research will not change with future research. The authors concluded that ‘future discovery of CWD transmission to humans cannot be entirely ruled out on the basis of current studies, particularly in the light of possible decades-long incubation periods for CWD prions in humans and recommended to exercise caution when handling potentially contaminated material and explore CWD management opportunities’.
Among the more recent studies not included in the systematic review by Waddell et al. (2018), Abrams et al. (2018) have investigated the rates of human prion disease in States of the USA with and without CWD, to examine the possibility of undetermined zoonotic transmission. Although final results of this study have not been published yet, the authors concluded that ‘while higher prion disease mortality rates in certain categories of states with CWD in free-ranging cervids were noted, additional stratified analyses did not reveal markedly elevated rates for potentially sensitive subgroups that would be suggestive of zoonotic transmission. Unknown confounding factors or other biases may explain state- by-state differences in prion disease mortality’.
Maddox et al. (2019) conducted a retrospective cohort study of 1,546 residents in 15 counties of the State of Wisconsin in which CWD has been confirmed among harvested free-ranging deer. By linking three databases, the study aimed to evaluate causes of mortality in individuals potentially exposed to CWD. The results of the study have not been published yet but preliminary results identified individuals that consumed CWD-positive deer but with no matches in the National Prion Disease Pathology Surveillance Center (NPDPSC) neuropathology database. Due to the long incubation period, should transmission to humans occur, many years of vital status tracking are needed.
The potential variability of phenotypes of prion disease in humans and the potential for association with a zoonotic strain of CWD is an increasing area of concern in CWD-endemic regions given the impossibility of knowing what the phenotype of human CWD prions would present with or whether they would be distinct from sporadic CJD cases. One example of a study looking at this aspect is the current analysis of the molecular diversity of CJD cases in patients who resided in Alberta and Saskatchewan (Canada) at their time of death (Myskiw et al., 2019). In a similar study, frozen brain tissues from all available sCJD cases archived in the NPDPSC from a US State with a high incidence of CWD are being analysed, looking for unusual patterns, characteristics and/or distribution of PrPSc in comparison with sCJD samples from States that have not detected CWD (Liu et al. (2019)).
3.4.2. Exposure assessment
There are two distinct routes of potential exposure of humans to the CWD agent(s):
1) Handling and manipulation by professionals (including industrial workers), hunters, consumers, etc., of dead bodies, carcasses, meat cuts, animal by-products including risk material and meat, meat products and offal infected with the CWD agent(s).
2) Consumption of meat, meat products and offal from animals infected with the CWD agent(s). The assessment of CWD risk to humans, generically defined as the probability of transmission to humans through the handling and/or consumption of meat and meat products from cervids is currently impossible, but could hypothetically be defined at two levels:
1) At the individual level, as the probability that at least one human is exposed to the CWD agent, acquiring the infection and developing either a known, an emergent or a new TSE.
2) At the population level, as the number of new human TSE cases in a defined population (incidence).
Considering each of these routes in turn, there is no evidence of anyone having acquired a human prion disease by handling and butchering infected animals of any species. However, the exposure of humans via direct contact (wounds, skin lacerations) while handling this type of material cannot be ruled out. Exposure to infected meat at household level may occur when consumers handle purchased raw meat, meat products or offal or, for home-slaughtered or hunted cervids when carcasses are butchered and dressed. The frequency of exposure through handling of fresh meat, meat products or offal will be different between professionals and consumers. However, ToR3 only requires the consideration of the risk of transmission to humans through the consumption of cervid meat and meat products.
The most likely source of exposure and the only one considered in this Scientific Opinion, is through the consumption of cervid meat, meat products and offal sourced from infected animals. Two events must occur for a human to be exposed: the animal must be infected with a TSE in which abnormal PrP/infection is present in edible peripheral tissues, mainly the musculoskeletal (including blood) and lymphatic systems and the consumer must have access to meat, meat products or offal from such animals in which the abnormal prion has not been inactivated by physicochemical or any other processing.
There are no studies in the scientific literature aimed to derive the amount of CWD infectivity potentially present in different tissues of susceptible species. Several studies describe the presence/ absence of detectable PrP in a range of tissues (see table 1 in EFSA BIOHAZ Panel, 2017). A single study (Gavin et al., 2019) has attempted to estimate, via mathematical modelling, the titre of infectivity that would pass, through abattoir killed or field dressed deer, into the human food chain and the environment. This study assumed that infectivity in red deer infected with CWD would be peripherally distributed and with a pathogenesis similar to classical scrapie. The model estimated that the total infectivity in a red deer carcass would be approximately 83,000 mouse IC log ID50 units, compared with around 22,000 in a scrapie-infected sheep carcass, mainly due to the size difference between sheep and red deer. The model estimated that around 13% (11,000 mouse IC log ID50 units) of the total infectivity would enter the food chain through either the farmed or wild route.
For the probability of exposure to the CWD agent(s):
• At the individual level, consumers of meat, meat products and offal derived from CWD-infected cervids will be exposed to the CWD agent(s) and, to a lesser extent, via the handling of infected material with strain(s) causing peripheral tissue distribution of infectivity in CWDinfected cervids. As stated in a previous EFSA Opinion on CWD (EFSA BIOHAZ Panel, 2018), even if specific tissues harbouring most of the infectivity were removed from the food chain, therefore reducing the human dietary exposure to infectivity, consumers would still be exposed to the CWD agent(s) via consumption of meat and meat products.
• At the population level, not only it is important to consider the strain(s) of agent in susceptible cervid species that are usually consumed (reindeer, moose, red deer), but also the prevalence of each CWD strain in each of these species. This would provide an overall estimation of the probability of exposure of EU citizens to the CWD agents/strains. However, there is no conclusive knowledge about the range of agents/strains of CWD in the European cervid population, their tissue distribution in infected animals or their prevalence in each/any of the populations. Therefore, the overall exposure of humans to CWD in the EU cannot be estimated.
3.4.3. Recommendations on possible additional control measures to address the risks identified
Recommendations that would reduce/eliminate human exposure to CWD all relate to the reduction or removal of infected tissues from the food chain by:
• Systematic testing: Only allowing human consumption of meat, meat products and offal sourced from animals that have been tested negative for CWD.
• Targeted measures: Prohibition of harvesting/hunting susceptible species or the introduction of compulsory testing of animals before human consumption in/from declared infected premises/ areas (e.g. a farm, or a surveillance PSU (Section 3.6), region, country, etc.).
• Systematic removal of high-risk tissues from all cervids intended for human consumption with no requirement for testing.
3.4.4. Concluding remarks
• Due to uncertainties and lack of data, it is not possible to conduct a risk assessment of CWD in humans and to directly quantify the human risk at either individual or population levels. The risk to humans through consumption of meat, meat products and offal derived from CWDinfected cervids cannot be directly assessed; only the probability of exposure to the CWD agent(s).
• Lack of comprehensive data on both the tissue distribution of infectivity in European cases and the prevalence of the CWD gent in each of the species, increases the uncertainty around human exposure and related risk factors.
• The available epidemiological studies have not shown any evidence of association between human TSE and NA CWD. However, these studies suffer from many methodological and logistic constraints.
• A recent systematic review concluded that the long incubation periods in human TSE mean that current studies do not definitely exclude any potential for CWD to transmit to humans.
• Even if the specific tissues harbouring most of the infectivity were removed from the food chain, therefore reducing the human dietary exposure to infectivity, consumers would still be exposed to the CWD agent(s) via consumption of meat and meat products from infected animals.
• Exclusion from the food chain of the whole carcass of any infected animal would be required to eliminate human dietary exposure. This could be facilitated by the preliminary testing of animals intended for consumption and/or the prohibition of harvesting or hunting susceptible species in infected premises/areas.
3.5. Situation of CWD in Europe: latest results
In 2018, Norway ‘embarked in an unprecedented eradication campaign of CWD in Nordfjella area where all the cases of CWD in reindeer have been found so far. As a result, between 10 August 2017 and 14 May 2018, 582 reindeer were culled during the normal hunting seasons, 1,399 reindeer were shot dead by professional marksmen. An additional 43 reindeer were found dead due to natural causes, making the total of the wild reindeer population removed by the eradication programme 2,024 wild reindeer’ (Mysterud and Rolandsen, 2018).
A recent study analysing the data of the Nordfjella area estimated the apparent CWD prevalence at 1.2% of adults in the infected population of wild reindeer, while the estimated true prevalence was 1.6% (Viljugrein et al., 2019).
The results of the surveillance conducted in cervids for TSE in the European countries have been summarised in the Tables 7 and 8. Before 2018, European countries had tested cervid populations for TSE in a very heterogeneous and inconsistent way (for a review of the EU surveillance before 2016 see EFSA BIOHAZ Panel, 2017, 2018), with Romania accounting for more than 90% of all cervids tested in the EU in the last 3 years.
Following the confirmation of the first case of CWD in Europe, the European Commission through Annex III of Regulation (EC) No. 999/2001, amended by Commission Regulation (EU) 2017/1972, enforced the implementation of a 3-year monitoring programme for CWD from 1 January 2018 to 31 December 2020 in the six MS that have a wild and/or farmed and/or semi-domesticated population of moose and/or reindeer: Estonia, Finland, Latvia, Lithuania, Poland and Sweden.
The programme requires the identification of geographically based PSU, which shall cover all territories in which cervid populations are present, for farmed and captive cervids and for wild and semi-domesticated cervids. The sampling strategy is two-stage: sample all PSU if the identified PSU list contains less than 100, or a random sample of 100 PSU if the identified PSU list contains more than 100. Within each selected PSU, a target sample of 30 risk animals is required.7 If an MS identifies fewer than 3,000 risk animals either among wild/semi-domesticated or farmed/captive cervids, it may extend the monitoring to hunted or slaughtered cervids declared fit for human consumption with the objective of approaching a total number of 3,000 wild and semi-domesticated cervids tested at the national level over the 3-year period that is relevant to it.
According to the Regulation, the risk animals include:
• For farmed and captive cervids:
fallen/culled farmed or captive cervids, defined as farmed or captive cervids found dead on the enclosed territory in which they are kept, during transport or at slaughterhouse, as well as farmed or captive cervids killed for health/age reasons;
clinical/sick farmed or captive cervids, defined as farmed or captive cervids showing abnormal behavioural signs and/or locomotor disturbances and/or as being generally in poor condition;
slaughtered farmed cervids which have been declared unfit for human consumption.
• For wild and semi-domesticated cervids:
fallen/culled wild or semi-domesticated cervids, defined as cervids found dead in the wild as well as semi-domesticated cervids found dead or killed for health/age reasons;
road- or predator-injured or killed cervids, defined as wild or semi-domesticated cervids hit by road vehicles, by trains or attacked by predators;
clinical/sick wild and semi-domesticated cervids, defined as wild and semi-domesticated cervids which are observed as showing abnormal behavioural signs and/or locomotor disturbances and/or as being generally in poor health condition;
wild hunted cervids and slaughtered semi-domesticated cervids which have been declared unfit for human consumption.
The total number of tested cervids in Europe in 2018 (as reported to EFSA) was 41,322, with 80% of these (33,037) tested by Norway where seven new cases (six in reindeer and one in a moose) were confirmed.
The remaining 20% were tested by EU MSs, apart from 100 reindeer tested by Iceland. Twelve MSs reported tested cervids, ranging from four each by Austria and Hungary, to Romania, the MS with the largest throughput in the EU, which tested 2,387, 75% of them wild roe deer.
In 2018, the six MS conducting mandatory surveillance tested a total 5,110 cervids, of which 4,674 (91.5%) were wild animals, mostly roe deer and red deer and 436 (8.5%) were captive, farmed or semi-domesticated, with more than half of them being semi-domesticated reindeer tested in Finland (Table 7).
The most common target group was the ‘hunted/slaughtered fit for human consumption’ (HSHC) that is not a ‘risk animals’ category and that group accounted for 59.5% of all cervids tested by the six MS. The rest were risk animals in the different target groups (SUS: clinical suspect animals; RK: Road/ predator killed; FC: fallen/culled; HSNHC: hunted/slaughtered not fit for human consumption). There is a huge variability between countries in the proportion of cervids tested in the HSHC, ranging from 5% tested by Sweden to 94.2% by Latvia or 84.8% by Lithuania (Table 8).
Up to 20 September 2019, 28 cases have been reported in Europe: 19 wild reindeer, four moose and one red deer in Norway and since the mandatory surveillance started in 2018 one moose in Finland and three moose in Sweden. The first Finnish case was reported in March 2018 as a 15-year-old moose that was found dead in Kuhmo (Kainuu region), in Easter Finland, near the border with the Russian Federation. It was positive in brain using Bio-Rad and IDEXX ELISA rapid tests and negative in the tested lymph nodes (Korpenfelt, 2019).
The first Swedish case was reported on 26 March 2019 as a 16-year-old female, euthanised because it was emaciated and showed circling and abnormal behaviour in the area of Arjeplog, municipality of Norrbotten, north of Sweden, ~ 400 km from the closest area where Norwegian cases in moose had been identified and ~ 950 km from where the Finnish moose case was found. It was positive using Bio-Rad TeSeE ELISA, Bio-Rad TeSeE WB and in immunohistochemistry in the brainstem and negative using Bio-Rad TeSeE ELISA and IHC in the retropharyngeal lymph node (Gavier-Widen, 2019). Preliminary results show a similar presentation to that of the CWD observed in moose in Norway and in Finland, but further analyses are needed to confirm possible similarities.
The second Swedish moose, also a 16-year-old female that was emaciated and showing behavioural changes, was found in Arvidsjaur, 70 km from the first case, in late May 2019. It was positive using Bio-Rad TeSeE ELISA and Bio-Rad TeSeE WB in the brainstem and negative using BioRad TeSeE ELISA in the retropharyngeal lymph node (Gavier-Widen, 2019). The third Swedish moose was an at least 9-year-old female, shot during the normal hunting season in the same area as the two previous cases and without any signs of illness.8
It is premature to make any assessment of the effectiveness of the monitoring programme in the six selected countries. It is important to remember that the aims of the proposed surveillance system are twofold: (1) to detect disease in countries where CWD has not yet been detected, using a predefined design prevalence based on previous known occurrence in newly infected areas in NA; and (2) to estimate prevalence in areas where disease has been detected (EFSA BIOHAZ Panel, 2017).
The logistical constraints of implementing such a programme at national level cannot be underestimated, hence the slow start of some of the countries during the first year of implementation. However, the detection of three cases already in two of the six countries at early stages of the programme leads to two immediate and preliminary conclusions: (1) it is of paramount importance to conduct active surveillance for CWD to ascertain the actual distribution of the disease in susceptible species of European cervids; and (2) the distribution and prevalence of CWD in Europe may be underestimated as the three species known to be susceptible to CWD in Europe, namely reindeer, moose and red deer, only accounted for 5.8%, 17.3% and 19% of all cervids tested in the six countries in 2018, with one case in moose found during that period and only four of every 10 cervids tested so far have been from the high-risk target groups.
For example, in a large country with more than 100 PSU defined, assuming a perfect random sampling of PSU and risk animals within the PSU and the same surveillance results as in Finland in 2018, the prevalence of CWD in the subpopulation of moose in the fallen/culled risk category would be 1/176 = 0.57% (95% CI: 0.01–3.1%). There are no surveillance data for Sweden in 2019 with which to make similar estimations.
Table 7: Number of tested cervids for TSE in the EU and European Economic Area (EEA) reporting countries for the period 2016–2018. In parentheses, the number of CWD cases
snip...
3.5.1. Concluding remarks
• A recent study analysing the data of the Nordfjella area estimated the apparent CWD prevalence at 1.2% of adults in the infected population of wild reindeer, while the estimated true prevalence was 1.6% (Viljugrein et al., 2019).
• The current mandatory surveillance programme in six EU MS has led to the detection of the first cases of CWD in the European Union, in a moose in Finland and in three moose in Sweden.
• Based on the available active and passive surveillance data from the EU as a whole, the overall situation of the disease is still unknown: CWD could be present in any of the other four MS under mandatory surveillance and/or in any of the other 22 MS not subject to mandatory surveillance. The available data on the prevalence of CWD in Sweden and Finland are still limited.
3.6. Risk factors for the spread of CWD in Europe
CWD in NA and Europe affects cervid species whose geographic ranges overlap with those of several other wild and domesticated species. Based on the experience gained in NA, CWD can be considered highly contagious, with infected individuals contributing to the spread of the disease through direct contact and/or through the shedding of the CWD agent(s) in the environment, where it remains infectious for a long time. Furthermore, the CWD agent(s) can be transported by other animal species (i.e. scavengers) or as a consequence of human activities, leading to a wider exposure of cervids and other potentially susceptible species to CWD. Therefore, among known prion diseases, CWD seems to have the widest potential species range, a notion which can have significant impact for understanding the biology of the CWD epidemics, for designing surveillance systems and control measures and for estimating the risks for food safety and human health.
As mentioned in Section 3.5, six EU MS are currently implementing mandatory surveillance. Due to the low throughput (data only available for 1 year of the 3-year cycle), no conclusions can yet be drawn about the prevalence of CWD in Finland and Sweden or the presence of disease in the remaining four countries. The uncertainty about the presence of the disease in the rest of Europe is even higher.
Except for the recent data from Norway, any information on host susceptibility, transmission and spread of CWD is based on the situation in NA. Previous European risk assessments (Defra, 2016a,b, 2018) have assumed that the disease, if it occurred in Europe, would have most likely been imported from NA and would therefore behave similarly in European cervid populations. However, the data emerging from the characterisation of the recently identified European cervid isolates (see Section 3.3) indicate that these European isolates are molecularly and biologically distinct from those identified in NA.
Given the uncertainties associated with the actual geographical distribution of CWD in Europe and the possible transmissibility of the different strains (known and unknown) in Europe, the following description of potential risk factors for the spread of CWD in Europe assumes two hypothetical scenarios, drawing on knowledge of CWD and other TSE in domestic animals and without any reference to specific locations where the disease is/might be present.
3.6.1. Scenario development
The description of the current scientific evidence on the characteristics of European CWD isolates (see Section 3.1) has implications for their potential capacity to spread naturally within cervid populations. In particular, the presence/absence of detectable PrPSc outside the CNS is thought to be an indication of the probability of spread under field conditions. While CNS involvement is a consistent feature of all clinical TSE cases regardless of species, the presence or absence of detectable PrPSc in peripheral tissues is more of a continuum, with some phenotypes presenting early accumulations of PrPSc, while others only accumulate limited amounts, or none. These differences may be associated either with strain or host genotype, or a combination of the two (for recent review of the cervid context, see Section 3.2.2 of the EFSA BIOHAZ Panel, 2018). For example, most cases of classical scrapie and NA CWD have widespread peripheral tissue involvement, the extent of which is affected by genotype and both are contagious under field conditions. BSE, H- and L-type BSE and atypical/Nor98 scrapie, conversely, have little or no detectable PrPSc in peripheral tissues (Benestad et al., 2003; Wells et al., 2005; Andreoletti et al., 2011; Stack et al., 2011; EFSA, 2014) and tend to present as individual cases within herds/flocks. (It is important to note that while the term ‘atypical’ is often applied to this latter phenotype, this does not mean that they necessarily share the same biochemical or biological properties, or zoonotic potential; see Appendix A.5) The NA elk, however, is in-between, with a low amounts of abnormal PrP deposition (Race et al., 2007) associated with longer incubation periods (Moore et al., 2018) and low prevalence (Mysterud and Edmunds, 2019). These differences allow the description for developing hypothetical epidemiological scenarios of what can be considered representative of the extremes of this phenotypic spectrum:
• A contagious form presenting with peripheral distribution of PrPSc/infectivity, similar to the wellknown presentation of CWD in NA and classical scrapie in small ruminants with susceptible PrP genotypes. It is assumed, for this scenario, that infected animals would be able to transmit disease horizontally under field conditions and that infection could also be spread via environmental contamination by either live animals (e.g. through saliva, urine, faeces) or carcass disintegration. Subsequent dissemination could occur as a result of human activity, fomites and/ or scavengers or via the feed chain.
• A non-contagious form presenting little or no detectable involvement of peripheral tissues, akin to BSE in cattle or atypical/Nor98 scrapie in small ruminants. It is assumed, for this scenario, that infection would be less likely to transmit horizontally under field conditions and that environmental contamination by live animals would be minimal. Environmental contamination could still arise from the CNS of disintegrating carcasses and be spread via human activity, fomites and/or scavengers or via the feed chain.
Disease can spread by:
• extending the geographic extent of a focus to a new area/region/country: mainly by natural migration of infected animals and by the translocation of infected cervids by humans;
• once introduced into a herd or population, the local spread of the agent is associated with the rate of contacts between animals or the environmental contamination. Behavioural and social factors of the different susceptible and non-susceptible species present explain the transmission rate of the disease and the consequent spread to non-infected animals within the population of interest.
In both cases, the agent(s) must be released from the infected individual(s), hence allowing other non-infected animals to be exposed resulting in further release or translocation and giving rise to:
• a new individual being infected that, if it is of a susceptible species, will develop clinical disease and will be capable of shedding infectivity in excreta throughout most of the incubation period if the disease phenotype includes PrP accumulation in peripheral tissues
• a subclinical or carrier animal, in which some abnormal PrP accumulates, but the animal does not develop clinical disease within its lifetime. Such animals may or may not shed infectivity in excreta, potentially over prolonged periods.
• a passive carrier, in which infection does not establish itself and infected material passes through the gut and into the environment via faeces in a relatively short time postconsumption (e.g. non-susceptible species such as predators, scavengers and carrion birds)
The two working scenarios may or not reflect the ability and the extent to which any of them can contribute to the transmission and spread of the disease. These scenarios do not account either for the possibility of the biological properties of an isolate changing on passage through another host species (EFSA BIOHAZ Panel, 2015).
3.6.2. Identification of risk factors
In the context of this Opinion, a risk factor for the spread of CWD in Europe will be considered as any feature that increases the likelihood of a non-infected animal becoming exposed and infected in areas where the disease has already been identified, or in areas not yet considered as infected.
The risk factors for the spread of prion disease have been widely described in the published literature and extensively reviewed in publications and published national risk assessments (most recently in UK and Norway). It is beyond the scope of this Opinion to undertake a further extensive literature review, particularly as it is likely that European and NA isolates differ from one another (see Sections 3.1 and 3.2) and may present with different, and as yet unknown, risks.
The table of risk factors below (Table 9) is a summary of all previously identified risks for the spread of prion disease assessed against the two hypothetical scenarios. The criteria applied for the inclusion of an ‘identified risk factor’ for either scenario are based on three components:
1) The biological plausibility of the release of the agent or of the exposure to the agent from an infected individual even if there is only a theoretical likelihood of occurrence (a theoretical risk factor).
2) A hypothesis raised from the field observation of the distribution of the disease based on descriptive epidemiological studies (a hypothetical risk factors).
3) The reporting of a risk factor as an output of analytical epidemiological studies in which the association between its exposure and the disease occurrence has been shown to be statistically significant (a confirmed risk factor).
The studies included in Table 9 have been classified, based on their design (Rothman et al., 2008; Dohoo et al., 2009) into intervention vs observational studies. The latter are further distinguished into analytical studies that are designed to test aetiological hypotheses and quantify the effect of risk factors (i.e. cohort studies, case–control studies and cross-sectional studies) vs descriptive studies (i.e. case reports and case series) that are considered as hypothesis-screening studies. By combining descriptive data and assumptions, epidemiological hypotheses may also be supported (but not tested) by mathematical simulation models.
The biological plausibility of the involvement of a factor in the spread may be suggested by nonepidemiological studies or qualitative risk assessments or reviews, so these were considered as sources able to suggest ‘theoretical risk factors’. Due to the uncertainties associated with both the unknown European epidemiological situation and the differences between involved strains, it is not possible to assess the epidemiological relevance of any of the listed risk factors even in the NA context, let alone in the European one.
However, the strength of the evidence for the causal role of each group of risk factors can be appraised. For this purpose, a score-based ranking (as proposed by Dohoo et al., 2009) has been applied based on the different informative potential of the studies:
• score = A: if the risk factor has been proposed through intervention studies (strongest evidence);
• score = B: if through cohort studies;
• score = C: if through case–control studies;
• score = D: if through cross-sectional studies;
• score = E: if through descriptive studies (i.e. an epidemiologically screened hypothesis) or mathematical simulation models;
• score = F: if through biologically plausible hypotheses alone, based on non-epidemiological studies or qualitative risk assessments or reviews (weakest evidence).
Based on the above inclusion criteria, Table 9 shows a list of groups of potential risk factors for the spread of CWD in Europe within or between areas/regions/countries, with the indication of the studies used to source each risk factor from the literature and their score. Finally, all factors depending on, or affected, by human practices (with the exception of rearing cervids in captivity) and therefore possible targets for preventive measures, have been highlighted.
A general conceptual map (Figure 1) has been developed to show all the factors mentioned in the list and to summarise the relationships among them within theoretical risk pathways. This map also highlights potential targets for interventions that could be used as preventive measures against the spread of disease.
Table 9: Groups of risk factors according to the two working scenarios (I: contagious animal vs II: non-contagious animal)
snip...
Figure 1: Conceptual map summarising the relationship among risk factors within risk pathways and potential targets for preventive measures
snip...
3.6.3. Concluding remarks
• The identification of risk factors associated with the spread of the disease can only be based on the epidemiological and biological understanding of NA CWD outbreaks, although the biological characterisation of the European isolates indicates that they differ from the known NA strains.
• The presence/absence of detectable PrPSc in the peripheral tissues as well as the CNS of affected animals can be used as an indicator of the probability of natural spread and animals assigned to different categories based on their pathogenesis. Both infected carriers and passive carriers are thought to be involved in the dissemination of the agent.
• Two distinct, hypothetical working scenarios have been built on these categories: a contagious form (Scenario 1) affecting animals which can spread infectivity through direct contacts with other animals and/or contamination of the environment and a non-contagious form (Scenario 2) that is transmitted through environmental contamination from infected carcasses or via human activity, scavengers or via the feed chain.
• Thirteen main groups of risk factors have been identified based on their biological plausibility to spread CWD. Some of them are supported by epidemiological evidence from NA CWD.
• The only risk factors for the spread of CWD affecting exclusively Scenario 1 refer to animal to animal contact which will increase through the aggregation of live animals, promoted, or not, by human activities.
• All other risk factors refer to natural or man-mediated movement or translocation of wild or farmed/free ranging animals and to environmental contamination and the subsequent exposure of animals to contaminated soil or vegetation. This can occur at the point of contamination (close to a fallen animal) or following translocation of contaminated materials by humans or scavengers. These risks will also vary depending on the social structures of different species and by habitat and the geography of specific regions. In wild populations, the co-existence of different species makes it important to consider all the identified risk factors in both scenarios.
• Risk reduction through intervention would be possible for some man-mediated risk factors, namely activities leading to the translocation or aggregation of both wild and farmed live animals, as well as fallen stock management and appropriate disposal of carcasses and slaughter by-products.
3.7. Uncertainty analysis
The sources of uncertainty associated with the available data have been summarised in tabular format (Table 10), describing the nature or cause of the uncertainty. The factors contributing to the list of uncertainties are mostly missing or incomplete data on disease prevalence, pathogenesis and isolate characterisation, affecting the entire Opinion and the answers to all of the ToRs.
Table 10: Sources of uncertainty identified in the risk assessment
snip...end...see full text;
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home